Emerg­ing from stealth mode, Aard­vark rounds up enough cash to put its lead drug through Prad­er-Willi PhII

When Aard­vark Ther­a­peu­tics CEO Tien Lee start­ed his work on the biotech’s lead can­di­date, ap­petite sup­pres­sion was the goal for the small mol­e­cule.  Soon af­ter, his team start­ed to see added ben­e­fits with low­er blood glu­cose lev­els and an­ti-in­flam­ma­to­ry ac­tiv­i­ty. On the tail end of that, the com­pa­ny has emerged from stealth mode and an­nounced to­day that they’ve raised enough cash in the B round to cov­er mid-stage de­vel­op­ment work.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN